The following text has been accessed from https://en.wikipedia.org/wiki/Graft-versus-host_disease at Fri Aug 9 02:19:39 IST 2019
Creative_Commons_Attribution-ShareAlike_License




















****** Graft-versus-host disease ******
From Wikipedia, the free encyclopedia
Jump_to_navigation Jump_to_search
 This article may be confusing_or_unclear to readers. In particular, it seems
 to contain some contradictions. Please help us clarify_the_article. There
 might be a discussion about this on the_talk_page. (July 2011)(Learn_how_and
 when_to_remove_this_template_message)
Graft-versus-host disease
Specialty Emergency_medicine [Edit_this_on_Wikidata]
Graft-versus-host disease (GvHD) is a medical_complication following the
receipt of transplanted_tissue_from_a_genetically_different_person. GvHD is
commonly associated with stem_cell_transplants such as those that occur with
bone marrow transplants. GvHD also applies to other forms of transplanted
tissues such as solid organ transplants.
White_blood_cells of the donor's immune system which remain within the donated
tissue (the graft) recognize the recipient (the host) as foreign (non-self).
The white blood cells present within the transplanted tissue then attack the
recipient's body's cells, which leads to GvHD. This should not be confused with
a transplant_rejection, which occurs when the immune system of the transplant
recipient rejects the transplanted tissue; GvHD occurs when the donor's immune
system's white blood cells reject the recipient. The underlying principle
(alloimmunity) is the same, but the details and course may differ. GvHD can
also occur after a blood_transfusion if the blood_products used have not been
irradiated or treated with an approved pathogen reduction system.
⁰
***** Contents *****
    * 1_Signs_and_symptoms
          o 1.1_Types
    * 2_Causes
          o 2.1_Transfusion-associated_GvHD
          o 2.2_Thymus_transplantation
          o 2.3_Thymoma-associated_multiorgan_autoimmunity_(TAMA)
    * 3_Mechanism
    * 4_Prevention
    * 5_Treatment
    * 6_Clinical_research
    * 7_HIV_elimination
    * 8_See_also
    * 9_References
    * 10_Further_reading
    * 11_External_links
***** Signs and symptoms[edit] *****
Mouse colon impacted by acute graft-versus-host disease.
In the classical sense, acute graft-versus-host-disease is characterized by
selective damage to the liver, skin (rash), mucosa, and the gastrointestinal
tract. Newer research indicates that other graft-versus-host-disease target
organs include the immune system (the hematopoietic_system, e.g., the bone
marrow and the thymus) itself, and the lungs in the form of immune-mediated
pneumonitis[1]. Biomarkers can be used to identify specific causes of GvHD,
such as elafin in the skin.[2] Chronic graft-versus-host-disease also attacks
the above organs, but over its long-term course can also cause damage to the
connective_tissue and exocrine_glands[3] .
Acute GvHD of the GI_tract can result in severe intestinal inflammation,
sloughing of the mucosal membrane, severe diarrhea, abdominal pain, nausea, and
vomiting[4]. This is typically diagnosed via intestinal biopsy. Liver GvHD is
measured by the bilirubin level in acute patients[5]. Skin GvHD results in a
diffuse red maculopapular_rash[6], sometimes in a lacy pattern.
Mucosal damage to the vagina can result in severe pain and scarring, and
appears in both acute and chronic GvHD. This can result in an inability to have
sexual_intercourse.[7]
Acute GvHD is staged as follows: overall grade (skin-liver-gut) with each organ
staged individually from a low of 1 to a high of 4. Patients with grade IV GvHD
usually have a poor prognosis. If the GvHD is severe and requires intense
immunosuppression involving steroids and additional agents to get under
control, the patient may develop severe infections[8] as a result of the
immunosuppression and may die of infection. However, a 2016 study found that
the prognosis for patients with grade IV GvHD has improved in recent years[9].
In the oral_cavity, chronic graft-versus-host-disease manifests as lichen
planus with a higher risk of malignant_transformation to oral squamous_cell
carcinoma[10] in comparison to the classical oral lichen planus. Graft-versus-
host-disease-associated oral_cancer may have more aggressive behavior with
poorer prognosis, when compared to oral cancer in non-hematopoietic stem cell
transplantation patients.[11]
**** Types[edit] ****
In the clinical setting, graft-versus-host-disease is divided into acute and
chronic forms, and scored or graded on the basis of the tissue affected and the
severity of the reaction.[12][13]
    * The acute or fulminant form of the disease (aGvHD) is normally observed
      within the first 100 days post-transplant,[14] and is a major challenge
      to transplants owing to associated morbidity and mortality.[15]
    * The chronic form of graft-versus-host-disease (cGvHD) normally occurs
      after 100 days. The appearance of moderate to severe cases of cGVHD
      adversely influences long-term survival.[16]
***** Causes[edit] *****
GvHD pathology
Three criteria, known as the Billingham criteria, must be met in order for GvHD
to occur.[17]
    * An immuno-competent graft is administered, with viable and functional
      immune cells.
    * The recipient is immunologically different from the donor â histo-
      incompatible.
    * The recipient is immunocompromised and therefore cannot destroy or
      inactivate the transplanted cells.
After bone marrow transplantation, T_cells present in the graft, either as
contaminants or intentionally introduced into the host, attack the tissues of
the transplant recipient after perceiving host tissues as antigenically
foreign. The T cells produce an excess of cytokines, including TNF-Î± and
interferon-gamma (IFNÎ³). A wide range of host antigens can initiate graft-
versus-host-disease, among them the human_leukocyte_antigens (HLA)[18].
However, graft-versus-host disease can occur even when HLA-identical siblings
are the donors[19]. HLA-identical siblings or HLA-identical unrelated donors
often have genetically different proteins (called minor_histocompatibility
antigens) that can be presented by major_histocompatibility_complex (MHC)
molecules to the donor's T-cells, which see these antigens as foreign and so
mount an immune response.[20]
Antigens most responsible for graft loss are HLA-DR (first six months), HLA-B
(first two years), and HLA-A (long-term survival).[21]
While donor T-cells are undesirable as effector cells of graft-versus-host-
disease, they are valuable for engraftment by preventing the recipient's
residual immune_system from rejecting the bone marrow graft (host-versus-
graft). In addition, as bone marrow transplantation is frequently used to treat
cancer, mainly leukemias, donor T-cells have proven to have a valuable graft-
versus-tumor effect[22]. A great deal of current research on allogeneic bone
marrow transplantation involves attempts to separate the undesirable graft-vs-
host-disease aspects of T-cell physiology from the desirable graft-versus-tumor
effect[23].
**** Transfusion-associated GvHD[edit] ****
Main article: Transfusion-associated_graft_versus_host_disease
This type of GvHD is associated with transfusion of un-irradiated blood to
immunocompromised recipients. It can also occur in situations in which the
blood donor is homozygous and the recipient is heterozygous for an HLA
haplotype. It is associated with higher mortality (80â90%) due to involvement
of bone marrow lymphoid tissue, however the clinical manifestations are similar
to GVHD resulting from bone marrow transplantation. Transfusion-associated GvHD
is rare in modern medicine. It is almost entirely preventable by controlled
irradiation of blood products to inactivate the white blood cells (including
lymphocytes) within.[24]
**** Thymus transplantation[edit] ****
Thymus_transplantation may be said to be able to cause a special type of GvHD
because the recipient's thymocytes would use the donor thymus cells as models
when going through the negative_selection to recognize self-antigens, and could
therefore still mistake own structures in the rest of the body for being non-
self. This is a rather indirect GvHD because it is not directly cells in the
graft itself that causes it but cells in the graft that make the recipient's T
cells act like donor T cells. It can be seen as a multiple-organ autoimmunity
in xenotransplantation experiments of the thymus between different species.[25]
Autoimmune disease is a frequent complication after human allogeneic thymus
transplantation, found in 42% of subjects over 1 year post transplantation.[26]
However, this is partially explained by the fact that the indication itself,
that is, complete DiGeorge_syndrome, increases the risk of autoimmune disease.
[27]
**** Thymoma-associated multiorgan autoimmunity (TAMA)[edit] ****
A GvHD-like disease called thymoma-associated_multiorgan_autoimmunity (TAMA)
can occur in patients with thymoma. In these patients rather than a donor being
a source of pathogenic T cells, the patient's own malignant thymus produces
self-directed T cells. This is because the malignant thymus is incapable of
appropriately educating developing thymocytes to eliminate self-reactive T
cells. The end result is a disease virtually indistinguishable from GvHD.[28]
***** Mechanism[edit] *****
The pathophysiology of GvHD includes three phases:[29]
   1. The afferent phase: activation of APC (antigen_presenting_cells)
   2. The efferent phase: activation, proliferation, differentiation and
      migration of effector cells
   3. The effector phase: target tissue destruction
Activation of APC occurs in the first stage of GvHD. Prior to haematopoietic
stem cell transplantation, radiation or chemotherapy results in damage and
activation of host tissues, especially intestinal mucosa. This allows the
microbial products to enter and stimulate pro-inflammatory cytokines such as
IL-1 and TNF-Î±. These proinflammatory cytokines increase the expression of MHC
and adhesion molecules on APCs, thereby increasing the ability of APC to
present antigen.[30] The second phase is characterized by the activation of
effector cells. Activation of donor T-cells further enhances the expression of
MHC and adhesion molecules, chemokines and the expansion of CD8 + and CD4 + T-
cells and guest B-cells. In the final phase, these effector cells migrate to
target organs and mediate tissue damage, resulting in multiorgan failure.[31]
***** Prevention[edit] *****
    * DNA-based tissue typing allows for more precise HLA matching between
      donors and transplant patients, which has been proven to reduce the
      incidence and severity of GvHD and to increase long-term survival.[32]
    * The T-cells of umbilical cord blood (UCB) have an inherent immunological
      immaturity,[33] and the use of UCB stem cells in unrelated donor
      transplants has a reduced incidence and severity of GvHD.[34]
    * Methotrexate, cyclosporin and tacrolimus are common drugs used for GvHD
      prophylaxis[35].
    * Graft-versus-host-disease can largely be avoided by performing a T-cell-
      depleted bone marrow transplant. However, these types of transplants come
      at a cost of diminished graft-versus-tumor effect, greater risk of
      engraftment failure, or cancer relapse,[36] and general immunodeficiency,
      resulting in a patient more susceptible to viral, bacterial, and fungal
      infection. In a multi-center study, disease-free survival at 3 years was
      not different between T cell-depleted and T cell-replete transplants.[37]
***** Treatment[edit] *****
Intravenously administered glucocorticoids, such as prednisone, are the
standard of care in acute GvHD[15] and chronic GVHD.[38] The use of these
glucocorticoids is designed to suppress the T-cell-mediated immune onslaught on
the host tissues; however, in high doses, this immune-suppression raises the
risk of infections and cancer relapse. Therefore, it is desirable to taper off
the post-transplant high-level steroid doses to lower levels, at which point
the appearance of mild GVHD may be welcome, especially in HLA mis-matched
patients, as it is typically associated with a graft-versus-tumor effect.
[citation_needed]. Cyclosporine and tacrolimus are calcineurin_inhibitors. Both
substances are structurally different but have the same mechanism of action.
Cyclosporin binds to the cytosolic protein Peptidyl-prolyl cis-trans isomerase
A (known as cyclophilin), while tacrolimus binds to the cytosolic protein
Peptidyl-prolyl cis-trans isomerase FKBP12. These complexes inhibit
calcineurin, block dephosphorylation of the transcription factor NFAT of
activated T-cells and its translocation into the nucleus.[39] Standard
prophylaxis involves the use of cyclosporine for six months with methotrexate.
Cyclosporin levels should be maintained above 200 ng/ml.[40] Other substances
that have been studied for GvHD treatment include, for example: sirolimus,
pentostatin, etanercept, and alemtuzumab.[40]
In August 2017 the US_FDA approved ibrutinib to treat chronic GvHD after
failure of one or more other systemic treatments.[41]
***** Clinical research[edit] *****
There are a large number of clinical trials either ongoing or recently
completed in the investigation of graft-versus-host disease treatment and
prevention.[42]
On May 17, 2012, Osiris Therapeutics announced that Canadian health regulators
approved Prochymal, its drug for acute graft-versus host disease in children
who have failed to respond to steroid treatment. Prochymal is the first stem
cell_drug to be approved for a systemic disease.[43]
In January 2016, Mesoblast released results of a Phase2 clinical trial on 241
children with acute Graft-versus-host disease, that was not responsive to
steroids.[44] The trial was of a mesenchymal stem cell therapy known as
remestemcel-L or MSC-100-IV. Survival rate was 82% (vs 39% of controls) for
those who showed some improvement after 1 month, and in the long term 72% (vs
18% of controls) for those that showed little effect after 1 month.[44]
***** HIV elimination[edit] *****
Graft versus host disease has been implicated in eliminating several cases of
HIV, including The_Berlin_Patient and 6 others in Spain. [45]
***** See also[edit] *****
    * Graft-versus-tumor_effect
    * Immunosuppression
    * Transplant_rejection
***** References[edit] *****
   1. ^Morisse-Pradier, H.; Nove-Josserand, R.; Philit, F.; Senechal, A.;
      Berger, F.; Callet-Bauchu, E.; Traverse-Glehen, A.; Maury, J.M.; et al.
      (2016). "Graft-versus-host disease, a rare complication of lung
      transplantation". Revue de Pneumologie Clinique. 72 (1): 101â107. doi:
      10.1016/j.pneumo.2015.05.004. PMID 26209034.
   2. .mw-parser-output cite.citation{font-style:inherit}.mw-parser-output
      .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation .cs1-lock-
      free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/
      65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:
      right .1em center}.mw-parser-output .citation .cs1-lock-limited a,.mw-
      parser-output .citation .cs1-lock-registration a{background:url("//
      upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/
      9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em
      center}.mw-parser-output .citation .cs1-lock-subscription a{background:
      url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-
      2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right
      .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-
      registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-
      parser-output .cs1-registration span{border-bottom:1px dotted;cursor:
      help}.mw-parser-output .cs1-ws-icon a{background:url("//
      upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/
      12px-Wikisource-logo.svg.png")no-repeat;background-position:right .1em
      center}.mw-parser-output code.cs1-code{color:inherit;background:
      inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-
      error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error
      {font-size:100%}.mw-parser-output .cs1-maint{display:none;color:
      #33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-
      output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-
      parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-
      left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-
      wl-right{padding-right:0.2em}
   3. ^Paczesny, S.; Levine, J.E.; Hogan, J.; Crawford, J.; Braun, T.M.; Wang,
      H.; Faca, V.; Zhang, Q.; et al. (2009). "Elafin_is_a_Biomarker_of_Graft
      Versus_Host_Disease_of_the_Skin". Biology of Blood and Marrow
      Transplantation. 15 (2): 13â4. doi:10.1016/j.bbmt.2008.12.039.
      PMC 2895410.
   4. ^Ogawa, Y.; Shimmura, S.; Dogru, M.; Tsubota, K. (2010). "Immune
      processes and pathogenic fibrosis in ocular chronic graft-versus-host
      disease and clinical manifestations after allogeneic hematopoietic stem
      cell transplantation". Cornea. 29 (Nov Supplement 1): S68â77. doi:
      10.1097/ICO.0b013e3181ea9a6b. PMID 20935546.
   5. ^"Graft-versus-host_disease". MedlinePlus. National Library of Medicine.
      Retrieved 6 May 2019.
   6. ^Krejci, M.; Kamelander, J.; Pospisil, Z.; Mayer, J. (2012). "Kinetics of
      bilirubin and liver enzymes is useful for predicting of liver graft-
      versus-host disease". Neoplasma. 59 (3): 264â268. doi:10.4149/
      neo_2012_034. PMID 22296496.
   7. ^ Feito-RodrÃ­guez, M.; de Lucas-Laguna, R.; GÃ³mez-FernÃ¡ndez, C.;
      Sendagorta-CudÃ³s, E.; Collantes, E.; Beato, M.J.; Boluda, E.R. (2013).
      "Cutaneous graft versus host disease in pediatric multivisceral
      transplantation". Pediatric Dermatology. 30 (3): 335â341. doi:10.1111/
      j.1525-1470.2012.01839.x. PMID 22957989.
   8. ^Spiryda, L; Laufer, MR; Soiffer, RJ; Antin, JA (2003). "Graft-versus-
      host disease of the vulva and/or vagina: Diagnosis and treatment".
      Biology of Blood and Marrow Transplantation. 9 (12): 760â5. doi:
      10.1016/j.bbmt.2003.08.001. PMID 14677115.
   9. ^"Graft-versus-host_disease". MedlinePlus. National Library of Medicine.
      Retrieved 6 May 2019.
  10. ^El-Jawahri, A.; Li, S.; Antin, J.H.; Spitzer, T.R.; Armand, P.A.;
      Koreth, J.; Nikiforow, S.; Ballen, K.K.; Ho, V.T.; Alyea, E.P.; Dey,
      B.R.; McAfee, S.L.; Glotzbecker, B.E.; Soiffer, R.J.; Cutler, C.S.; Chen,
      Y.B. (2016). "Improved Treatment-Related Mortality and Overall Survival
      of Patients with Grade IV Acute GVHD in the Modern Years". Biology of
      Blood and Marrow Transplantation: Journal of the American Society for
      Blood and Marrow Transplantation. 22 (5): 910â918. doi:10.1016/
      j.bbmt.2015.12.024. PMID 26748160.
  11. ^Tsukada, S.; Itonaga, H.; Taguchi, J.; Miyoshi, T.; Hayashida, S.; Sato,
      S.; Ando, K.; Sawayama, Y.; Imaizumi, Y.; Hata, T.; Umeda, M.; Niino, D.;
      Miyazaki, Y. (2019). "Gingival squamous cell carcinoma diagnosed on the
      occasion of osteonecrosis of the jaw in a patient with chronic GVHD".
      Rinsho Ketsueki. 60 (1): 22â27. doi:10.11406/rinketsu.60.22.
      PMID 30726819.
  12. ^Elad, Sharon; Zadik, Yehuda; Zeevi, Itai; Miyazaki, Akihiro; De
      Figueiredo, Maria A. Z.; Or, Reuven (2010). "Oral Cancer in Patients
      After Hematopoietic Stem-Cell Transplantation: Long-Term Follow-Up
      Suggests an Increased Risk for Recurrence". Transplantation. 90 (11):
      1243â4. doi:10.1097/TP.0b013e3181f9caaa. PMID 21119507.
  13. ^Martino R, Romero P, SubirÃ¡ M, Bellido M, AltÃ©s A, Sureda A, Brunet S,
      Badell I, Cubells J, Sierra J (1999). "Comparison of the classic
      Glucksberg criteria and the IBMTR Severity Index for grading acute graft-
      versus-host disease following HLA-identical sibling stem cell
      transplantation. International Bone Marrow Transplant Registry". Bone
      Marrow_Transplantation. 24 (3): 283â287. doi:10.1038/sj.bmt.1701899.
      PMID 10455367.
  14. ^Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ,
      Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell
      A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B,
      Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M,
      Vogelsang G, Flowers ME (2005). "National_Institutes_of_Health_consensus
      development_project_on_criteria_for_clinical_trials_in_chronic_graft-
      versus-host_disease:_I._Diagnosis_and_staging_working_group_report".
      Biology of Blood and Marrow Transplantation. 11 (12): 945â956. doi:
      10.1016/j.bbmt.2005.09.004. PMC 4329079. PMID 16338616.
  15. ^Funke, V.A.; Moreira, M.C.; Vigorito, A.C. (2016). "Acute and chronic
      Graft-versus-host disease after hematopoietic stem cell transplantation".
      Revista da AssociaÃ§Ã£o MÃ©dica Brasileira. 62 (supl 1): 44â50. doi:
      10.1590/1806-9282.62.suppl1.44. PMID 27982319.
  16. ^ a bGoker, H; Haznedaroglu, IC; Chao, NJ (2001). "Acute graft-vs-host
      disease Pathobiology and management". Experimental Hematology. 29 (3):
      259â77. doi:10.1016/S0301-472X(00)00677-9. PMID 11274753.
  17. ^Lee, Stephanie J.; Vogelsang, Georgia; Flowers, Mary E.D. (2003).
      "Chronic graft-versus-host disease". Biology of Blood and Marrow
      Transplantation. 9 (4): 215â33. doi:10.1053/bbmt.2003.50026.
      PMID 12720215.
  18. ^ Billingham, R.E. (1966). "The biology of graft-versus-host-reactions".
      Harvey Lectures. 1966-1967 (62): 21â78. PMID 4875305.
  19. ^Kanda, J. (2013). "Effect of HLA mismatch on acute graft-versus-host
      disease". International Journal of Hematology. 98 (3): 300â308. doi:
      10.1007/s12185-013-1405-x. PMID 23893313.
  20. ^Bonifazi, F.; Solano, C.; Wolschke, C.; Sessa, M.; et al. (2019). "Acute
      GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic
      peripheral blood stem-cell transplantation from HLA-identical siblings in
      patients with acute myeloid leukaemia in remission: final results of
      quality of life and long-term outcome analysis of a phase 3 randomised
      study". Lancet Haematology. 6 (2): e89âe99. doi:10.1016/S2352-3026
      (18)30214-X. PMID 30709437.
  21. ^Taylor CJ, Bolton EM, Bradley JA (2011). "Immunological_considerations
      for_embryonic_and_induced_pluripotent_stem_cell_banking". Philosophical
      Transactions_of_the_Royal_Society_B. 366 (1575): 2312â2322. doi:
      10.1098/rstb.2011.0030. PMC 3130422. PMID 21727137.
  22. ^Solomon S, Pitossi F, Rao MS (2015). "Banking_on_iPSC_â_is_it_doable
      and_is_it_worthwhile". Stem Cell Reviews. 11 (1): 1â10. doi:10.1007/
      s12015-014-9574-4. PMC 4333229. PMID 25516409.
  23. ^Falkenburg, J.H.F.; Jedema, I. (2017). "Graft_versus_tumor_effects_and
      why_people_relapse". Hematology: American Society of Hematology Education
      Program. December (1): 693â698. doi:10.1182/asheducation-2017.1.693.
      PMC 6142614. PMID 29222323.
  24. ^Sun, K.; Li, M.; Sayers, T.J.; Welniak, L.A.; Murphy, W.J. (2008).
      "Differential_effects_of_donor_T-cell_cytokines_on_outcome_with
      continuous_bortezomib_administration_after_allogeneic_bone_marrow
      transplantation". Blood. 112 (4): 1522â1529. doi:10.1182/blood-2008-03-
      143461. PMC 2515132. PMID 18539902.
  25. ^Moroff, G; Leitman, SF; Luban, NL (1997). "Principles_of_blood
      irradiation,_dose_validation,_and_quality_control". Transfusion. 37 (10):
      1084â1092. doi:10.1046/j.1537-2995.1997.371098016450.x. PMID 9354830.
  26. ^Xia, G.; Goebels, J.; Rutgeerts, O.; Vandeputte, M.; Waer, M. (2001).
      "Transplantation tolerance and autoimmunity after xenogeneic thymus
      transplantation". Journal of Immunology. 166 (3): 1843â1854. doi:
      10.4049/jimmunol.166.3.1843. PMID 11160231.
  27. ^Markert, M. Louise; Devlin, Blythe H.; McCarthy, Elizabeth A.; Chinn,
      Ivan K.; Hale, Laura P. (2008). "Thymus_Transplantation". In Lavini,
      Corrado; Moran, Cesar A.; Morandi, Uliano; et al. (eds.). Thymus Gland
      Pathology: Clinical, Diagnostic, and Therapeutic Features. pp. 255â267.
      doi:10.1007/978-88-470-0828-1_30. ISBN 978-88-470-0827-4.
  28. ^Markert, M. L.; Devlin, B. H.; Alexieff, M. J.; Li, J.; McCarthy, E. A.;
      Gupton, S. E.; Chinn, I. K.; Hale, L. P.; et al. (2007). "Review_of_54
      patients_with_complete_DiGeorge_anomaly_enrolled_in_protocols_for_thymus
      transplantation:_Outcome_of_44_consecutive_transplants". Blood. 109 (10):
      4539â47. doi:10.1182/blood-2006-10-048652. PMC 1885498. PMID 17284531.
  29. ^Wadhera A, Maverakis E, Mitsiades N, Lara PN, Fung MA, Lynch PJ (October
      2007). "Thymoma-associated multiorgan autoimmunity: a graft-versus-host-
      like disease". J Am Acad Dermatol. 57 (4): 683â689. doi:10.1016/
      j.jaad.2007.02.027. PMID 17433850.
  30. ^Tabbara, Imad; Elbahesh, Ehab; Rafei, Hind; Nassereddine, Samah (2017-
      04-01). "Acute_Graft_Versus_Host_Disease:_A_Comprehensive_Review".
      Anticancer Research. 37 (4): 1547â1555. ISSN 0250-7005. PMID 28373413.
  31. ^Roncarolo, Maria-Grazia; Battaglia, Manuela (August 2007). "Regulatory
      T-cell immunotherapy for tolerance to self antigens and alloantigens in
      humans". Nature Reviews Immunology. 7 (8): 585â598. doi:10.1038/
      nri2138. PMID 17653126.
  32. ^Zhang, L.; Chu, J.; Yu, J.; Wei, W. (7 December 2015). "Cellular and
      molecular mechanisms in graft-versus-host disease". Journal of Leukocyte
      Biology. 99 (2): 279â287. doi:10.1189/jlb.4ru0615-254rr. PMID 26643713.
  33. ^Morishima, Y.; Sasazuki, T; Inoko, H; Juji, T; Akaza, T; Yamamoto, K;
      Ishikawa, Y; Kato, S; et al. (2002). "The clinical significance of human
      leukocyte antigen (HLA) allele compatibility in patients receiving a
      marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched
      unrelated donors". Blood. 99 (11): 4200â6. doi:10.1182/
      blood.V99.11.4200. PMID 12010826.
  34. ^Grewal, S. S.; Barker, JN; Davies, SM; Wagner, JE (2003). "Unrelated
      donor hematopoietic cell transplantation: Marrow or umbilical cord
      blood?". Blood. 101 (11): 4233â44. doi:10.1182/blood-2002-08-2510.
      PMID 12522002.
  35. ^Laughlin, Mary J.; Barker, Juliet; Bambach, Barbara; Koc, Omer N.;
      Rizzieri, David A.; Wagner, John E.; Gerson, Stanton L.; Lazarus, Hillard
      M.; et al. (2001). "Hematopoietic Engraftment and Survival in Adult
      Recipients of Umbilical-Cord Blood from Unrelated Donors". New England
      Journal of Medicine. 344 (24): 1815â22. doi:10.1056/
      NEJM200106143442402. PMID 11407342.
  36. ^TÃ¶rlÃ©n, J.; RingdÃ©n, O.; Garming-Legert, K.; Ljungman, P.; Winiarski,
      J.; Remes, K.; ItÃ¤lÃ¤-Remes, M.; Remberger, M.; Mattsson, J. (2016). "A
      prospective_randomized_trial_comparing_cyclosporine/methotrexate_and
      tacrolimus/sirolimus_as_graft-versus-host_disease_prophylaxis_after
      allogeneic_hematopoietic_stem_cell_transplantation". Haematologica. 101
      (11): 1417â1425. doi:10.3324/haematol.2016.149294. PMC 5394879.
      PMID 27662016.
  37. ^Hale, G; Waldmann, H (1994). "Control of graft-versus-host disease and
      graft rejection by T cell depletion of donor and recipient with Campath-
      1 antibodies. Results of matched sibling transplants for malignant
      diseases". Bone Marrow Transplantation. 13 (5): 597â611. PMID 8054913.
  38. ^Wagner, John E; Thompson, John S; Carter, Shelly L; Kernan, Nancy A;
      Unrelated Donor Marrow Transplantation Trial (2005). "Effect of graft-
      versus-host disease prophylaxis on 3-year disease-free survival in
      recipients of unrelated donor bone marrow (T-cell Depletion Trial): A
      multi-centre, randomised phase IIâIII trial". The Lancet. 366 (9487):
      733â41. doi:10.1016/S0140-6736(05)66996-6. PMID 16125590.
  39. ^Menillo, S A; Goldberg, S L; McKiernan, P; Pecora, A L (2001).
      "Intraoral psoralen ultraviolet a irradiation (PUVA) treatment of
      refractory oral chronic graft-versus-host disease following allogeneic
      stem cell transplantation". Bone Marrow Transplantation. 28 (8): 807â8.
      doi:10.1038/sj.bmt.1703231. PMID 11781637.
  40. ^Liu, J; Farmer JD, Jr; Lane, WS; Friedman, J; Weissman, I; Schreiber, SL
      (23 August 1991). "Calcineurin is a common target of cyclophilin-
      cyclosporin A and FKBP-FK506 complexes". Cell. 66 (4): 807â15. doi:
      10.1016/0092-8674(91)90124-h. PMID 1715244.
  41. ^ a bMandanas, Romeo A. "Graft_Versus_Host_Disease_Treatment_&
      Management:_Medical_Care". Medscape. Retrieved 30 August 2017.
  42. ^ FDA_expands_ibrutinib_indications_to_chronic_GVHD._Aug_2017
  43. ^ search_of_clinicaltrials.gov_for_Graft-versus-host_disease
  44. ^"World's_First_Stem-Cell_Drug_Approval_Achieved_in_Canada". The National
      Law Review. Drinker Biddle & Reath LLP. 2012-06-12. Retrieved 2012-07-01.
  45. ^ a b"Increased_Survival_Using_MSB_Cells_In_Children_With_aGVHD".
      Retrieved 22 Feb 2016.
  46. ^"Immune_war_with_donor_cells_after_transplant_may_wipe_out_HIV". ?.
      NewScientist. 2017-05-03. Retrieved 2018-11-23.
***** Further reading[edit] *****
    * Ferrara JLM, Deeg HJ, Burakoff_SJ. Graft-Vs.-Host Disease: Immunology,
      Pathophysiology, and Treatment. Marcel Dekker, 1990
ISBN 0-8247-9728-0
Polsdorfer, JR Gale Encyclopedia of Medicine: Graft-vs.-host disease
***** External links[edit] *****
                   D
                       * ICD-10: T86.0
Classification         * ICD-9-CM: 279.50
                       * MeSH: D006086
                       * DiseasesDB: 5388
External resources     * MedlinePlus: 001309
                       * eMedicine: med/926 ped/893 derm/478
    * v
    * t
    * e
Organ_transplantation
                               * Allotransplantation
Types                                o ABOi
                               * Autotransplantation
                               * Xenotransplantation
                               * Bone
                               * Bone_marrow
                               * Brain
                               * Corneal
                               * Face
                               * Hand
                               * Head
                               * Heart
                               * Heartâlung
                               * Intestine
                               * Kidney
Organs_and_tissues             * Liver
                                     o Living_donor
                               * Lung
                               * Pancreas
                                     o Islet_cell
                               * Penis
                               * Skin
                               * Spleen
                               * Testicle
                               * Thymus
                               * Uterus
                               * Vagina
                               * Bone_grafting
Medical_grafting               * Skin_grafting
                               * Vascular_grafting
                               * Non-heart-beating_donation
Organ_donation                 * Organ_harvesting
                               * Organ_trade
                               * Graft-versus-host disease
Complications                  * Post-transplant_lymphoproliferative_disorder
                               * Transplant_rejection
                               * Balttransplant
                               * BC_Transplant_Society
                               * Eurotransplant
                               * Gift_of_Life_Marrow_Registry
                               * Human_Tissue_Authority
Transplant networks            * LifeSharers
and government departments     * National_Marrow_Donor_Program
                               * NOD-Lb
                               * National_Transplant_Organization
                               * NHS_Blood_and_Transplant
                               * Scandiatransplant
                               * Trillium_Gift_of_Life_Network
                               * United_Network_for_Organ_Sharing
                               * Anthony_Nolan
                               * Bloodwise
                               * DKMS
Advocacy organizations         * Donate_Life_America
                               * Halachic_Organ_Donor_Society
                               * Kidney_Foundation_of_Canada
                               * National_Kidney_Foundation
                               * ORGANIZE
                               * American_Society_of_Nephrology
Joint societies                * American_Society_of_Transplantation
                               * Canadian_Society_of_Transplantation
                               * Organ_transplantation_in_different_countries
                               * Organ_transplantation_in_China
Countries                      * Organ_transplantation_in_Israel
                               * Organ_transplantation_in_Japan
                               * Gurgaon_kidney_scandal
                                        * Christiaan_Barnard
                                        * James_D._Hardy
                           Heart        * Adrian_Kantrowitz
                                        * Richard_Lower
                                        * Norman_Shumway
                                        * J._Hartwell_Harrison
                           Kidney       * John_P._Merrill
                                        * Joseph_Murray
                                        * Michael_Woodruff
                                        * Fikri_Alican
                           Liver        * James_D._Hardy
People                                  * Thomas_Starzl
                                        * Fikri_Alican
                           Lung         * Joel_D._Cooper
                                        * Vladimir_Demikhov
                                        * James_D._Hardy
                           Pancreas     * Richard_C._Lillehei
                           Penis        * AndrÃ©_van_der_Merwe
                                        * Alexis_Carrel
                           Other        * Jean-Michel_Dubernard
                                        * Donna_Mansell
                                        * Bruce_Reitz
                               * List_of_organ_transplant_donors_and
                                 recipients
                               * Biomedical_tissue
                               * Edmonton_protocol
                               * Eye_bank
Related topics                 * Immunosuppressive_drugs
                               * Lung_allocation_score
                               * Machine_perfusion
                               * Total_body_irradiation
                               * Frankenstein's_monster
    * v
    * t
    * e
Consequences of external_causes (T66âT78, 990â995)
                 Elevated       Hyperthermia
                                Heat_syncope
                                Hypothermia
                                Immersion_foot_syndromes
                                      Trench_foot
                                      Tropical_immersion_foot
Temperature                           Warm_water_immersion_foot
                 Reduced        Chilblains
                                Frostbite
                                Aerosol_burn
                                Cold_intolerance
                                Acrocyanosis
                                Erythrocyanosis_crurum
                       Radiation_poisoning
                       Radiation_burn
                       Chronic_radiation_keratosis
                       Eosinophilic,_polymorphic,_and_pruritic_eruption
                       associated_with_radiotherapy
Radiation              Radiation_acne
                       Radiation-induced_cancer
                       Radiation_recall_reaction
                       Radiation-induced_erythema_multiforme
                       Radiation-induced_hypertrophic_scar
                       Radiation-induced_keloid
                       Radiation-induced_morphea
                     * Hypoxia/Asphyxia
                     * Barotrauma
                           o Aerosinusitis
                           o Decompression_sickness
Air                  * High_altitude
                           o Altitude_sickness
                           o Chronic_mountain_sickness
                           o HAPE
                           o HACE
Food                 * Starvation
                     * Physical_abuse
Maltreatment         * Sexual_abuse
                     * Psychological_abuse
                     * Motion_sickness
Travel               * Seasickness
                     * Airsickness
                     * Space_adaptation_syndrome
                     * Hypersensitivity
                           o Anaphylaxis
Adverse effect             o Angioedema
                           o Allergy
                           o Arthus_reaction
                     * Adverse_drug_reaction
                     * Electrical_injury
Other                * Drowning
                     * Lightning_injuries
                     * Dermatosis_neglecta
                     * Pinch_mark
                     * Pseudoverrucous_papules_and_nodules
                     * Sclerosing_lymphangitis
                     * Tropical_anhidrotic_asthenia
                     * UV-sensitive_syndrome
                             Black_heel_and_palm
                             Equestrian_perniosis
                             Jogger's_nipple
                             Pulling_boat_hands
Ungrouped                    Runner's_rump
skin conditions              Surfer's_knots
resulting from               Tennis_toe
physical factors             Vibration_white_finger
                             Weathering_nodule_of_ear
                             Wrestler's_ear
                             Coral_cut
                             Painful_fat_herniation
                       Uranium_dermatosis
                             Skin_pop_scar
                             Skin_track
                             Slap_mark
                             Pseudoacanthosis_nigricans
                             Narcotic_dermopathy
    * v
    * t
    * e
Hypersensitivity and autoimmune_diseases (279.5â6)
                                    * Atopic_eczema
                                    * Allergic_urticaria
                                    * Allergic_rhinitis (Hay fever)
                                    * Allergic_asthma
                                    * Anaphylaxis
                                    * Food_allergy
Type_I/allergy/atopy Foreign              o common allergies include: Milk
(IgE)                                     o Egg
                                          o Peanut
                                          o Tree_nut
                                          o Seafood
                                          o Soy
                                          o Wheat
                                    * Penicillin_allergy
                     Autoimmune     * Eosinophilic_esophagitis
                     Foreign    Hemolytic_disease_of_the_newborn
                                              * Autoimmune_hemolytic_anemia
                                              * Immune_thrombocytopenic_purpura
                                              * Bullous_pemphigoid
Type_II/ADCC                    Cytotoxic     * Pemphigus_vulgaris
    *     o IgM      Autoimmune               * Rheumatic_fever
          o IgG                               * Goodpasture_syndrome
                                              * GuillainâBarrÃ©_syndrome
                                "Type_V"/     * Graves'_disease
                                receptor      * Myasthenia_gravis
                                              * Pernicious_anemia
                                    * HenochâSchÃ¶nlein_purpura
                                    * Hypersensitivity_vasculitis
                                    * Reactive_arthritis
                     Foreign        * Farmer's_lung
Type_III                            * Post-streptococcal_glomerulonephritis
(Immune_complex)                    * Serum_sickness
                                    * Arthus_reaction
                                    * Systemic_lupus_erythematosus
                     Autoimmune     * Subacute_bacterial_endocarditis
                                    * Rheumatoid_arthritis
                     Foreign        * Allergic_contact_dermatitis
                                    * Mantoux_test
                                    * Diabetes_mellitus_type_1
                                    * Hashimoto's_thyroiditis
Type_IV/cell-                       * Multiple_sclerosis
mediated             Autoimmune     * Coeliac_disease
(T_cells)                           * Giant-cell_arteritis
                                    * Postorgasmic_illness_syndrome
                                    * Reactive_arthritis
                     GVHD           * Transfusion-associated_graft_versus_host
                                      disease
                                    * Hypersensitivity_pneumonitis
                                          o Allergic_bronchopulmonary
                     Foreign                aspergillosis
                                    * Transplant_rejection
                                    * Latex_allergy (I+IV)
Unknown/                            * SjÃ¶gren_syndrome
multiple                            * Autoimmune_hepatitis
                                    * Autoimmune_polyendocrine_syndrome
                     Autoimmune           o APS1
                                          o APS2
                                    * Autoimmune_adrenalitis
                                    * Systemic_autoimmune_disease

Retrieved from "https://en.wikipedia.org/w/index.php?title=Graft-versus-
host_disease&oldid=907967402"
Categories:
    * Immune_system_disorders
    * Transplantation_medicine
    * Noninfectious_immunodeficiency-related_cutaneous_conditions
    * Complications_of_surgical_and_medical_care
Hidden categories:
    * CS1:_long_volume_value
    * Wikipedia_articles_needing_clarification_from_July_2011
    * All_Wikipedia_articles_needing_clarification
    * All_articles_with_unsourced_statements
    * Articles_with_unsourced_statements_from_December_2012
***** Navigation menu *****
**** Personal tools ****
    * Not logged in
    * Talk
    * Contributions
    * Create_account
    * Log_in
**** Namespaces ****
    * Article
    * Talk
⁰
**** Variants ****
**** Views ****
    * Read
    * Edit
    * View_history
⁰
**** More ****
**** Search ****
[Unknown INPUT type][Search][Go]
**** Navigation ****
    * Main_page
    * Contents
    * Featured_content
    * Current_events
    * Random_article
    * Donate_to_Wikipedia
    * Wikipedia_store
**** Interaction ****
    * Help
    * About_Wikipedia
    * Community_portal
    * Recent_changes
    * Contact_page
**** Tools ****
    * What_links_here
    * Related_changes
    * Upload_file
    * Special_pages
    * Permanent_link
    * Page_information
    * Wikidata_item
    * Cite_this_page
**** In other projects ****
    * Wikimedia_Commons
**** Print/export ****
    * Create_a_book
    * Download_as_PDF
    * Printable_version
**** Languages ****
    * ÄeÅ¡tina
    * Deutsch
    * EspaÃ±ol
    * Gaeilge
    * íêµ­ì´
    * Italiano
    * ×¢××¨××ª
    * Nederlands
    * æ¥æ¬èª
    * Polski
    * PortuguÃªs
    * Suomi
    * Svenska
    * à¹à¸à¸¢
    * TÃ¼rkÃ§e
    * ä¸­æ
Edit_links
    * This page was last edited on 26 July 2019, at 14:02 (UTC).
    * Text is available under the Creative_Commons_Attribution-ShareAlike
      License; additional terms may apply. By using this site, you agree to the
      Terms_of_Use and Privacy_Policy. WikipediaÂ® is a registered trademark of
      the Wikimedia_Foundation,_Inc., a non-profit organization.
    * Privacy_policy
    * About_Wikipedia
    * Disclaimers
    * Contact_Wikipedia
    * Developers
    * Cookie_statement
    * Mobile_view
    * [Wikimedia_Foundation]
    * [Powered_by_MediaWiki]
